Zhejiang East Asia Pharmaceutical (SHA:605177) subsidiary Zhejiang Dongbang Pharmaceutical acquired the European CEP certificate for Cefaclor API (enzymatic method), according to a Monday filing with the Shanghai bourse.
Cefaclor is an antibacterial drug used to treat a variety of infections.
The acquisition of the certificate meant that the company's cefaclor API (enzyme method) had obtained access to the European market, which will help expand sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.